Please login to the form below
David Noble to leave Edelman
David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure
David Noble, managing director of Edelman's BioScience division has been made redundant as part of a management restructure.
Noble has been heading the agency's specialist medical communications business unit for more than three years. He is to leave this month following a three-week consultation process.
Steve Spurr who leads Edleman's ethical healthcare division will take over Noble's responsibilities.
Robert Phillips, Edelman UK CEO told PR Week: "The BioScience and Rx divisions will remain separate, but will be headed by Steve. We are reorganising internally to have more fluent interaction between the teams."
The BioScience division specialises in advisory board management, clinical trial recruitment/retention, market access support, publication planning, meetings and symposia.
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Biogen's ALS drug tofersen misses phase 3 endpoint
- What does HCP engagement look like in a post-Covid world?
- Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence
- Valneva COVID-19 vaccine more effective than AZ
- Real-world data highlights flu vaccine efficacy
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
No results were found
PMHub
Frontera Group
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...
Latest intelligence
- What does HCP engagement look like in a post-Covid world?
- HCP engagement has changed as a result of the Covid-19 pandemic, with pharmaceutical companies and agencies having to rapidly adjust to a new way of communicating. Digital channels have become...
- Breaking the silence: It’s time to talk about the menopause
- Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
